Sandoz Group AG (Sandoz Group AG) EBIT : $ Mil (TTM As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG EBIT?

Sandoz Group AG's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $332 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sandoz Group AG's annualized ROC % for the quarter that ended in Dec. 2023 was 5.50%. Sandoz Group AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 60.02%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Sandoz Group AG EBIT Historical Data

The historical data trend for Sandoz Group AG's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG EBIT Chart

Sandoz Group AG Annual Data

Trend

Dec22

Dec23

EBIT

1,191.00

332.00

Sandoz Group AG Quarterly Data
	Dec22	Dec23
EBIT	1,191.00	332.00

Competitive Comparison of Sandoz Group AG's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sandoz Group AG's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sandoz Group AG's EV-to-EBIT falls into.

Sandoz Group AG EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $ Mil.

Sandoz Group AG (OTCPK:SDZNY) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sandoz Group AG's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2022 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	1500 * ( 1 - 38.46% )	/	( (17706	+	15891)	/ 2 )
=	923.1	/	16798.5
=	5.50 %

where

	Invested Capital		(Q: Dec. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	17557	-	1789	-	( 74	-	max(0, 7914	-	5976	+	74	))
=	17706

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	19430	-	2430	-	( 1109	-	max(0, 5698	-	7572	+	1109	))
=	15891

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Sandoz Group AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2022		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	1328	/	( ( (1904 + max(-3048, 0))	+	(1850 + max(671, 0)) )	/	2 )
=	1328	/	( ( 1904	+	2521 )	/	2 )
=	1328	/	2212.5
=	60.02 %

where Working Capital is:

	Working Capital		(Q: Dec. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(2207	+	2124	+	320)	-	(1789	+	0	+	5910)
=	-3048

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(2615	+	2700	+	731)	-	(2430	+	0	+	2945)
=	671

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sandoz Group AG's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=		/	18622.288
	=	%

Sandoz Group AG EBIT Related Terms

Thank you for viewing the detailed overview of Sandoz Group AG's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Sandoz Group AG (Sandoz Group AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (OTCPK:SDZNY) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

SDZXF:USA SDZz:UK D8Y0:Germany SDZ:Switzerland

Address

Forum 1, Novartis Campus, Basel, CHE, CH-4056

Website

https://www.sandoz.com

Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as U.S.'s first biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in pipeline.

Sandoz Group AG (Sandoz Group AG) Headlines

From GuruFocus

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research • 02-14-2024

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research • 02-14-2024